CLEVELAND, OH – February 29, 2016
BioMotiv and Rutgers University announce the formation of Z53 Therapeutics, a new biotechnology startup to develop novel anti-cancer drugs that target tumors with p53 mutations. Z53 Therapeutics is based on intellectual property licensed from Rutgers University, developed from the laboratories of scientific founders Darren Carpizo, M.D., Ph.D., a Harrington Scholar-Innovator, and S. David Kimball, Ph.D.

Click here to read more